Abstract | PURPOSE: METHODS: A 23-month-old girl with TAR syndrome was treated with recombinant IL-6 (Sigosix; Serono Laboratories, Norwell, MA) at a dose of 7 micrograms/kg subcutaneously daily. Complete blood counts were monitored weekly. The child was closely monitored for any toxicity. RESULTS: After 3 weeks of therapy, the patient had an increase in platelet count from a baseline of 5,000 to 8,000/microliter to a maximal level of 33,000/microliter. She was platelet transfusion-independent during IL-6 therapy. Fevers and chills, the main toxicities encountered, were controlled with acetaminophen and ibuprofen. An increase in the IL-6 dose caused anemia with no further increase in platelet count. After discontinuation of the drug, her hemoglobin rose to baseline and the platelet count returned to pretreatment levels. CONCLUSIONS: We conclude that IL-6 may benefit some children with TAR syndrome. The role of IL-6 and other thrombopoietic agents in the treatment of TAR and other congenital thrombocytopenias deserves further clinical study.
|
Authors | V M Aquino, M M Mustafa, L Vaickus, R Wooley, G R Buchanan |
Journal | Journal of pediatric hematology/oncology
(J Pediatr Hematol Oncol)
1998 Sep-Oct
Vol. 20
Issue 5
Pg. 474-6
ISSN: 1077-4114 [Print] United States |
PMID | 9787323
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Interleukin-6
- Recombinant Proteins
|
Topics |
- Administration, Cutaneous
- Female
- Humans
- Infant
- Interleukin-6
(administration & dosage)
- Radius
(abnormalities)
- Recombinant Proteins
(administration & dosage)
- Syndrome
- Thrombocytopenia
(drug therapy, physiopathology)
|